JP2009532372A - 代謝障害の併用治療 - Google Patents

代謝障害の併用治療 Download PDF

Info

Publication number
JP2009532372A
JP2009532372A JP2009503119A JP2009503119A JP2009532372A JP 2009532372 A JP2009532372 A JP 2009532372A JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009532372 A JP2009532372 A JP 2009532372A
Authority
JP
Japan
Prior art keywords
methyl
compound
hydrogen
phenyl
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532372A5 (enExample
Inventor
ボーステル， リード ダブリュー． フォン
カービン エル． ホッジ，
Original Assignee
ウェルスタット セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェルスタット セラピューティクス コーポレイション filed Critical ウェルスタット セラピューティクス コーポレイション
Publication of JP2009532372A publication Critical patent/JP2009532372A/ja
Publication of JP2009532372A5 publication Critical patent/JP2009532372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009503119A 2006-03-31 2007-03-05 代謝障害の併用治療 Pending JP2009532372A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74402106P 2006-03-31 2006-03-31
PCT/US2007/063288 WO2007117791A2 (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009532372A true JP2009532372A (ja) 2009-09-10
JP2009532372A5 JP2009532372A5 (enExample) 2010-04-22

Family

ID=38581719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503119A Pending JP2009532372A (ja) 2006-03-31 2007-03-05 代謝障害の併用治療

Country Status (11)

Country Link
US (1) US8338480B2 (enExample)
EP (1) EP2001461A4 (enExample)
JP (1) JP2009532372A (enExample)
KR (1) KR20080106455A (enExample)
CN (1) CN101410105A (enExample)
AU (1) AU2007235145B2 (enExample)
CA (1) CA2647258A1 (enExample)
IL (1) IL194189A0 (enExample)
MX (1) MX2008012506A (enExample)
NZ (1) NZ571118A (enExample)
WO (1) WO2007117791A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129363A (ja) * 2007-09-07 2014-07-10 Childrens Hospital Medical Center 臨床サンプルにおける分泌性のルイス抗原およびシアル化抗原のレベルの疾患リスクの予測指標としての使用
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ｕｃｐ－１発現促進剤
JP2016027013A (ja) * 2014-06-24 2016-02-18 花王株式会社 Ｕｃｐ−１発現促進剤
JP2016027012A (ja) * 2014-06-24 2016-02-18 花王株式会社 Ｕｃｐ−１発現促進剤
JP2016509249A (ja) * 2012-12-21 2016-03-24 ドルビー ラボラトリーズ ライセンシング コーポレイション 知覚的基準に基づいてオブジェクト・ベースのオーディオ・コンテンツをレンダリングするためのオブジェクト・クラスタリング
US10098903B2 (en) 2009-07-06 2018-10-16 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341513C2 (ru) * 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических заболеваний
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009525982A (ja) * 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
WO2009091732A1 (en) * 2008-01-15 2009-07-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8829058B2 (en) * 2008-03-13 2014-09-09 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2005501012A (ja) * 2001-06-12 2005-01-13 ウェルスタット セラピューティクス コーポレイション 代謝障害治療用化合物
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2006127133A2 (en) * 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CN1543451A (zh) * 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
CA2502297C (en) * 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
CA2522738C (en) * 2003-04-30 2011-11-08 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
US7820721B2 (en) * 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501012A (ja) * 2001-06-12 2005-01-13 ウェルスタット セラピューティクス コーポレイション 代謝障害治療用化合物
WO2004073611A2 (en) * 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2005018628A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2006127133A2 (en) * 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014129363A (ja) * 2007-09-07 2014-07-10 Childrens Hospital Medical Center 臨床サンプルにおける分泌性のルイス抗原およびシアル化抗原のレベルの疾患リスクの予測指標としての使用
US11058697B2 (en) 2009-07-06 2021-07-13 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US12171773B2 (en) 2009-07-06 2024-12-24 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US11324765B2 (en) 2009-07-06 2022-05-10 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10098903B2 (en) 2009-07-06 2018-10-16 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
JP2016509249A (ja) * 2012-12-21 2016-03-24 ドルビー ラボラトリーズ ライセンシング コーポレイション 知覚的基準に基づいてオブジェクト・ベースのオーディオ・コンテンツをレンダリングするためのオブジェクト・クラスタリング
US9805725B2 (en) 2012-12-21 2017-10-31 Dolby Laboratories Licensing Corporation Object clustering for rendering object-based audio content based on perceptual criteria
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
JP2016027012A (ja) * 2014-06-24 2016-02-18 花王株式会社 Ｕｃｐ−１発現促進剤
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
JP2016027013A (ja) * 2014-06-24 2016-02-18 花王株式会社 Ｕｃｐ−１発現促進剤
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ｕｃｐ－１発現促進剤
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Also Published As

Publication number Publication date
NZ571118A (en) 2011-12-22
KR20080106455A (ko) 2008-12-05
IL194189A0 (en) 2009-08-03
CA2647258A1 (en) 2007-10-18
WO2007117791A2 (en) 2007-10-18
CN101410105A (zh) 2009-04-15
US8338480B2 (en) 2012-12-25
AU2007235145B2 (en) 2011-09-22
US20100292277A1 (en) 2010-11-18
AU2007235145A1 (en) 2007-10-18
WO2007117791A3 (en) 2008-08-21
EP2001461A4 (en) 2010-06-09
EP2001461A2 (en) 2008-12-17
MX2008012506A (es) 2008-10-14

Similar Documents

Publication Publication Date Title
US8338480B2 (en) Combination treatment of metabolic disorders
US11179359B2 (en) Treatment of NAFLD and NASH
JP6861795B2 (ja) アモジアキンおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
US8017652B2 (en) Activators of peroxisome proliferator-activated receptors
EP3880187A1 (en) Treatment of obesity and its complications
JP2006507303A (ja) 代謝障害の処置のための化合物
JP2006507303A5 (enExample)
JP4804353B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
AU2003299772C1 (en) Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
KR100798217B1 (ko) 당뇨병을 치료하기 위한 피탄산의 용도
JP2007269630A (ja) インスリン分泌促進剤
CN114364385B (zh) 用于对抗代谢疾病的组合物及其用途
KR102524408B1 (ko) 아모디아퀸 및 아르테수네이트계 약물을 유효성분으로 함유하는 제2형 당뇨병 예방 또는 치료용 약학적 조성물
JP2002220345A (ja) 脂肪肝改善剤
AU2003260380B2 (en) Use of a PPAR-alpha agonist to treat weight gain associated with a PPAR-gamma agonist treatment
CN1741799B (zh) 抗糖尿病药物的组合
HK40001639B (en) Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatmew of diabetes
JPWO2019225722A1 (ja) 代謝改善剤
HK40001639A (en) Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatmew of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130426